source
- FDA grants accelerated approval to Replimune’s melanoma therapy Tudriqev after two prior rejectionsThe Food and Drug Administration has granted accelerated approval to Replimune’s RP1 treatment, which will be marketed under the name Tudriqev, for patients with advanced melanoma. An advisory com…
- Takeda receives FDA approval for Orzeyful, first orexin agonist to treat all symptoms of narcolepsy type 1Takeda announced that the U.S. Food and Drug Administration has approved its drug oveporexton, which will be marketed under the name Orzeyful, for the treatment of narcolepsy type 1 in adults. The…